



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>6</sup> : <b>C12Q 1/68</b></p>	<b>A1</b>	<p>(11) International Publication Number: <b>WO 95/25180</b></p> <p>(43) International Publication Date: 21 September 1995 (21.09.95)</p>																														
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/US95/03339</p> <p>(22) International Filing Date: 14 March 1995 (14.03.95)</p> <p>(30) Priority Data: 08/215,081 16 March 1994 (16.03.94) US</p> <p>(71) Applicant: GEN-PROBE INCORPORATED [US/US]; 9880 Campus Point Drive, San Diego, CA 92121 (US).</p> <p>(72) Inventors: DATTA GUPTA, Nanibhushan; 4221 Kerwood Court, San Diego, CA 92130 (US). STULL, Paul, Dou- glas; Apartment 1317, 3717 Nobel Drive, San Diego, CA 92122 (US). SPINGOLA, Marc; 207 Chula Vista Place, Albuquerque, NM 87108 (US). KACIAN, Daniel, Louis; 3911 Tambor Road, San Diego, CA 92124 (US).</p> <p>(74) Agents: HEBER, Sheldon, O. et al.; Lyon &amp; Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AU, CA, JP, KR.</p> <p><b>Published</b> <i>With international search report.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/US95/03339</p> <p>(22) International Filing Date: 14 March 1995 (14.03.95)</p> <p>(30) Priority Data: 08/215,081 16 March 1994 (16.03.94) US</p> <p>(71) Applicant: GEN-PROBE INCORPORATED [US/US]; 9880 Campus Point Drive, San Diego, CA 92121 (US).</p> <p>(72) Inventors: DATTA GUPTA, Nanibhushan; 4221 Kerwood Court, San Diego, CA 92130 (US). STULL, Paul, Dou- glas; Apartment 1317, 3717 Nobel Drive, San Diego, CA 92122 (US). SPINGOLA, Marc; 207 Chula Vista Place, Albuquerque, NM 87108 (US). KACIAN, Daniel, Louis; 3911 Tambor Road, San Diego, CA 92124 (US).</p> <p>(74) Agents: HEBER, Sheldon, O. et al.; Lyon &amp; Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US).</p>	<p>(81) Designated States: AU, CA, JP, KR.</p> <p><b>Published</b> <i>With international search report.</i></p>																												
<p>(21) International Application Number: PCT/US95/03339</p> <p>(22) International Filing Date: 14 March 1995 (14.03.95)</p> <p>(30) Priority Data: 08/215,081 16 March 1994 (16.03.94) US</p> <p>(71) Applicant: GEN-PROBE INCORPORATED [US/US]; 9880 Campus Point Drive, San Diego, CA 92121 (US).</p> <p>(72) Inventors: DATTA GUPTA, Nanibhushan; 4221 Kerwood Court, San Diego, CA 92130 (US). STULL, Paul, Dou- glas; Apartment 1317, 3717 Nobel Drive, San Diego, CA 92122 (US). SPINGOLA, Marc; 207 Chula Vista Place, Albuquerque, NM 87108 (US). KACIAN, Daniel, Louis; 3911 Tambor Road, San Diego, CA 92124 (US).</p> <p>(74) Agents: HEBER, Sheldon, O. et al.; Lyon &amp; Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US).</p>	<p>(81) Designated States: AU, CA, JP, KR.</p> <p><b>Published</b> <i>With international search report.</i></p>																															
<p>(54) Title: ISOTHERMAL STRAND DISPLACEMENT NUCLEIC ACID AMPLIFICATION</p> <div style="text-align: center; margin: 20px 0;"> <p>(+) Primers</p> <table style="margin: auto;"> <tr> <td style="text-align: center;">1 (+)</td> <td style="text-align: center;">2 (+)</td> <td style="text-align: center;">3 (+)</td> <td style="text-align: center;">4 (+)</td> <td style="width: 20px;"></td> <td style="text-align: center;">Template (+sense)</td> </tr> <tr> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td></td> <td style="text-align: center;">_____</td> </tr> <tr> <td colspan="4" style="border-top: 1px solid black; height: 10px;"></td> <td></td> <td style="text-align: center;">_____</td> </tr> <tr> <td colspan="4"></td> <td></td> <td style="text-align: center;">4 (-) 3 (-) 2 (-) 1 (-)</td> </tr> <tr> <td colspan="4"></td> <td></td> <td style="text-align: center;">_____</td> </tr> </table> <p style="text-align: center;">(-) Primers</p> </div>			1 (+)	2 (+)	3 (+)	4 (+)		Template (+sense)	_____	_____	_____	_____		_____						_____						4 (-) 3 (-) 2 (-) 1 (-)						_____
1 (+)	2 (+)	3 (+)	4 (+)		Template (+sense)																											
_____	_____	_____	_____		_____																											
					_____																											
					4 (-) 3 (-) 2 (-) 1 (-)																											
					_____																											
<p>(57) Abstract</p> <p>Methods for amplifying target nucleic acid sequences using a nucleic acid polymerase lacking 5' exonuclease activity and a set of oligonucleotide primers. Preferably, a primer array is used. The primer array contains two sets of primers. One set contains at least two complementary primers. The other set contains at least two sense primers. Using the described methods, amplification can be carried out under essentially constant environmental conditions without the requirement for exonuclease activity or restriction endonuclease activity.</p>																																

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTIONIsothermal Strand Displacement  
Nucleic Acid AmplificationField of Invention

This invention relates to methods for amplifying nucleic acid sequences without thermal cycling.

Background of the Invention

5 This invention concerns diagnostic procedures and techniques for amplifying a nucleic acid sequence. The detection and quantitation of a specific nucleic acid sequence (*i.e.*, a target sequence) is an increasingly important technique having numerous applications including  
10 identifying and classifying microorganisms, diagnosing infectious diseases, detecting and characterizing genetic abnormalities, identifying genetic changes associated with cancer, studying genetic susceptibility to disease, measuring the response to various types of treatment,  
15 identifying criminal suspects, and resolving paternity disputes.

A common method for detecting and quantitating target nucleic acid sequences is nucleic acid hybridization. Nucleic acid hybridization, typically, uses a labeled  
20 nucleic acid probe having a nucleic acid sequence complementary to the target sequence. The probe is mixed with a sample suspected of containing the target sequence under conditions suitable for hybrid formation. The probe then hybridizes to the target sequence present in the sample.  
25 Hybridization can be detected by various techniques well known in the art. These techniques include selectively degrading the label present on unhybridized probe and then measuring the amount of label associated with the remaining hybridized probe (Arnold et al., PCT US88/02746).

30 Numerous methods are available for amplifying nucleic acid strands (*i.e.*, nucleic acid polymers) to increase the

amount of target sequence. These methods use the nucleic acid strand containing the target sequence as a template to produce a complementary nucleic acid strand containing the target sequence. Such methods include the polymerase chain reaction method (PCR), as described by Mullis et al., (See U.S. Patent Nos. 4,683,195, 4,683,202, and 4,800,159 and European Patent Application Nos. 86302298.4, 86302299.2, and 87300203.4, and Methods in Enzymology, Volume 155, 1987, pp. 335-350). PCR involves the use of a pair of specific oligonucleotides as primers for the two complementary strands of the double-stranded DNA containing the target sequence. The primers are chosen to hybridize at the ends of each of the complementary target strands, 3' of the target sequence. Template-dependent DNA synthesis, on each strand, can then be catalyzed using a thermostable DNA polymerase in the presence of the appropriate reagents. A thermal cycling process is required to form specific hybrids prior to synthesis and then denature the double stranded nucleic acid formed by synthesis. Repeating the cycling process geometrically amplifies the target sequence. A PCR method may also be used with an RNA target using RNA-dependent DNA polymerase to create a DNA template.

The PCR method has been coupled to RNA transcription by incorporating a promoter sequence into one of the primers used in the PCR reaction and then, after amplification by the PCR method, using the double-stranded DNA as a template for the transcription of single-stranded RNA. (See, e.g., Murakawa et al., DNA 7:287-295 (1988)). Other amplification methods use multiple cycles of RNA-directed DNA synthesis and transcription to amplify DNA or RNA targets (See, e.g., Burg et al., WO 89/1050; Gingeras et al., WO 88/10315 (sometimes called transcription amplification system or TAS); Kacian and Fultz, EPO Application No. 89313154; Davey and Malek, EPO Application No. 88113948.9; Malek et al., WO91/02818). Urdea, WO91/10746,

describe a method that achieves signal amplification using a T7 promoter sequence.

The ligase chain reaction (LCR) is described in European Patent Publication 320,308. This method requires at least four separate oligonucleotides, two of which hybridize to the same nucleic acid template so their respective 3' and 5' ends are juxtaposed for ligation. The hybridized oligonucleotides are then ligated forming a complementary strand on the nucleic acid template. The double-stranded nucleic acid is then denatured, and the third and fourth oligonucleotides are hybridized with the first and second oligonucleotides that were joined together. The third and fourth oligonucleotides are then ligated together. Amplification is achieved by further cycles of hybridization, ligation, and denaturation.

The Q $\beta$  replicase (Q $\beta$ R) method described in PCT Publication No. 87-06270 and U.S. Patent No. 4,786,600 uses a specific RNA probe which is capable of specific transcription by a replicase enzyme. The method requires the design and synthesis of RNA probes with replicase initiation sites.

Amplification methods using palindromic probes are described in EPO Publication Nos. 0427073A and 0427074A. The palindromic probe forms a hairpin with a nucleic acid target sequence. The probe contains a functional promoter located in the hairpin region from which RNA transcripts are produced.

Walker et al., Proc. Natl. Acad. Sci. U.S.A., 89:392-396 (Jan. 1992), Walker et al., Nucl. Acids Res. 20:1691-1696 (1992), European Patent Application No. EP 0 497 272 A1, and European Patent Application No. EP 0 500 224 A2, describe an oligonucleotide-driven amplification method using a restriction endonuclease. The restriction endonuclease nicks the DNA/DNA complex to enable an extension reaction and, therefore, amplification.

Becker, et al., EPO Application No. 88306717.5, describe an amplification method in which a primer is

hybridized to a nucleic acid sequence and the resulting duplex cleaved prior to the extension reaction and amplification.

Noonan, K.E. et al., Nucl. Acids Res. 16, 10366  
5 (1988), describe using random hexamers to prime reverse transcriptase in a random, nonspecific manner for the synthesis of cDNA from mRNA. Amplification of the desired target is accomplished with PCR.

Feinberg, A.P. et al., Anal. Biochem. 132, 6 (1983),  
10 and Liang, W. et al., Nucl. Acids Res. 16, 3579 (1988), describe the synthesis of DNA strands complementary to a DNA template by combining single-stranded DNA with random hexanucleotide primers, deoxynucleoside triphosphates, buffer, the Klenow fragment of *E. coli* DNA polymerase I,  
15 and a labeled deoxynucleoside triphosphate.

A related process, known as Random Priming Amplification (RPA) for amplifying nucleic acid is described by Hartley, U.S. Patent 5,043,272. According to Hartley, at columns 2-3, lines 63-2:

20 The process includes the steps of priming single-stranded template nucleic acid strands with an excess of random oligonucleotide primers and incubating the single-stranded template nucleic acid strands and excess random  
25 oligonucleotide primers in the presence of excess amounts of an inducing agent, a strand displacement agent, and nucleoside triphosphate substrates to randomly amplify nucleic acid strands.

### 30 Summary of the Invention

The present invention features methods for amplifying target nucleic acid sequences using a nucleic acid polymerase lacking 5' exonuclease activity and oligonucleotide primers. Alternatively, the method of the present  
35 invention may be performed using a nucleic acid polymerase having 5' exonuclease activity if the oligonucleotide

primers have a 5' modification which prevents or reduces nucleolytic digestion of the primers. Preferably, amplification is carried out using a primer array comprising two sets of primers. One set contains at least two  
5 primers complementary to the target nucleic acid. The other set contains at least two primers of the same sense as the target nucleic acid. Using the described methods amplification can be carried out under essentially constant environmental conditions without the requirement  
10 for exonuclease activity or restriction endonuclease activity. Preferably, amplification is carried out using a DNA template, and a DNA polymerase such as a modified *Bacillus stearothermophilus* (*Bst*) DNA polymerase which lacks 5' exonuclease activity.

15 The oligonucleotide members of each primer set are used as initiation points for template-dependent synthesis of a complementary nucleic acid strand, and to enhance displacement of the synthesized complementary strand. Thus, strand displacement and nucleic acid synthesis are  
20 carried out in one step. This is a surprising finding, and Applicant is unclear of the exact mechanism by which the procedure operates.

Only one set of primers is believed necessary to effectuate strand displacement and nucleic acid synthesis.  
25 A primer array is preferably used to amplify both the initial template and its complement to exponentially amplify a target sequence.

Preferably, the nucleic acid polymerase lacks 5' exonuclease activity, and the procedure is performed at  
30 higher temperatures than those at which enzymes such as the Klenow fragment of *E. coli* DNA polymerase I are optimally active. The reaction is more efficient at 43°C than at 37°C. Optimal efficiency is obtained at temperatures between 50°C and 70°C.

35 The method is preferably used on DNA. An RNA target sequence is preferably amplified by first creating a DNA

copy using, for example, reverse transcriptase. The DNA copy is then amplified by the methods described herein.

However, the present invention should be able to directly amplify an RNA sequence using an enzyme able to  
5 synthesize an RNA complementary strand on an RNA template. Such an enzyme preferably lacks 5' exonuclease activity. For example, QB replicase used in conjunction with manganese should be suitable for this purpose.

Thus, in a first aspect, the invention features a  
10 method for amplifying a target nucleic acid sequence by contacting a nucleic acid strand containing the target sequence with a nucleic acid polymerase lacking 5' exonuclease activity (5'-exo-minus polymerase), four different nucleotides, and at least two complementary  
15 oligonucleotide primers. Preferably, four different deoxynucleotides and/or three or more primers are used. The amplification is carried out under primer extension conditions at essentially constant temperature.

In related aspects amplification is carried out using  
20 a nucleic acid polymerase that has 5' exonuclease activity but under conditions wherein such activity is inhibited, and amplification is carried out using at least two complementary oligonucleotide primers in the absence of a restriction endonuclease active on the products of any  
25 extension reaction of said contacting step.

In another related aspect, the invention features a method for amplifying a target nucleic acid sequence by contacting a nucleic acid strand containing the target sequence with a nucleic acid polymerase lacking 5' exonuclease activity (5'-exo-minus polymerase), four  
30 different nucleotides, at least two complementary oligonucleotide primers, and at least two sense primers. The amplification is carried out under primer extension conditions at essentially constant temperature.  
35 Preferably, the total number of complementary primers and sense primers is more than 5.



The nucleic acid strand present prior to amplification serves as an initial nucleic acid template for the synthesis of a complementary strand containing the target sequence. The complementary strand can act as a  
5 nucleic acid template to produce strands analogous to the initial nucleic acid template. The analogous strands can act as nucleic acid templates. Thus, the resulting amplification of target sequence is geometric.

Primer extension conditions refer to conditions  
10 wherein template-dependent amplification initiated at an oligonucleotide primer can occur. Such conditions generally include provision of an appropriate buffer and, optionally, other chemicals that may stabilize the polymerase, or enhance primer extension reactions.

15 "Template" refers to a nucleic acid strand, such as DNA or RNA, which can serve as a substrate for the synthesis of a complementary nucleic acid strand.

A "target sequence" refers to a specific nucleic acid sequence contained on a single strand of an oligonucleo-  
20 tide or nucleic acid molecule, or the nucleic acid sequence complementary thereto.

A "complementary primer" refers to an oligonucleotide primer having a nucleic acid sequence complementary to a nucleic acid sequence present on the nucleic acid  
25 template. Complementary primers are designed to be complementary to nucleic acid sequences, on the nucleic acid template, in regions 3' to the target sequence.

By "complementary" is meant that the oligonucleotide primer can hybridize to a region of the nucleic acid  
30 template under the conditions of the contacting step so it can be extended in a primer extension reaction. Generally, such oligonucleotides have a region of complementarity to the template of between 15 and 100 bases, preferably between about 20 and 50 bases. Preferably the  
35 region of complementarity is 100% complementary. That is, each nucleotide in the primer complementary region can

hydrogen bond with a nucleotide present on the single-stranded template.

However, those of ordinary skill in the art will recognize that primers having a complementary region less  
5 than 100% complementary to the template will operate in this method. Generally, such complementarity can be as few as 15 out of 18 contiguous bases.

A "sense primer" refers to an oligonucleotide analogous to a nucleic acid sequence present on the  
10 nucleic acid template. A sense primer is designed to be analogous to a region on the template 5' of the target sequence.

By "analogous" is meant that the oligonucleotide has essentially the same, or equivalent, nucleotide sequence  
15 as that in the nucleic acid template. Thus, for example, the oligonucleotide may contain uracil in place of a thymine present in the nucleic acid template. The analogous oligonucleotides are preferably sufficiently  
20 duplicative of the template so they can act as a complementary primer when hybridized to a nucleic acid that is complementary to the nucleic acid template, under primer extension conditions.

Thus, reference to complementary primers and sense primers is made with respect to a particular template.  
25 The same primer can act as a complementary primer or a sense primer depending upon whether it is analogous to, or complementary to, a particular template.

Primer-dependent amplification of a target sequence present on a nucleic acid template is achieved in the  
30 contacting step. The degree of amplification has been found to increase with increasing numbers of primers. Examples are provided below using as many as 13 primers (seven sense and six complementary), and as few as two primers (two complementary primers). These examples  
35 illustrate the ability of primers to cause amplification and are not intended to limit the invention. Preferably, the complementary primer set and the sense primer set each

contain more than two primers. In preferred embodiments, at least 4 sense primers and 4 complementary primers are used; at least 7 sense primers and 7 complementary primers are used; and at least 10 sense primers and 10 complementary primers are used.

As illustrated in the Figure, a set of complementary primers comprise oligonucleotides complementary to the template in regions 3' of the target sequence. A set of sense primers comprise oligonucleotides analogous to the template in regions 5' of the target sequence on the same strand. The oligonucleotides are selected so a primer extension reaction is initiated on the nucleic acid template at a site different from the other oligonucleotide primers, and preferably at a site distinct from the region in which the other oligonucleotide primers form base pairs. Preferably, the oligonucleotides in a primer set are separated at their closest 5' and 3' ends from one another by 1 to 200 bases, and more preferably, are separated by between 1 and 10 bases.

By "four different nucleotides" is meant that adenosine (A), guanosine (G), cytidine (C) thymidine (T), and uridine (U) triphosphates, or an equivalent nucleotide which can be substituted for an adenosine, guanosine, cytidine, thymidine, or uridine nucleotide triphosphate, are present as substrates for nucleic acid synthesis. Preferably, deoxynucleotides are used.

By "amplifying" is meant increasing the number of target sequences.

By "contacting" is meant that the nucleic acid template, the nucleic acid polymerase, the four different nucleotides, and the oligonucleotide primer array are brought together under primer extension conditions.

By "essentially constant temperature" is meant that the user makes no attempt to raise or lower the temperature in any profound manner as is used in the polymerase chain reaction to alternatively carry out primer extension and denature the extension products. Thus, the tempera-

ture is kept below the temperature at which the template: primer extension product duplex dissociates. Preferably, the temperature is kept below 90°C. More preferably, the reaction temperature is maintained at about the optimum  
5 temperature for the reaction. Generally, such an optimum is between 42°C and 60°C and is preferably between 50°C and 70°C.

In preferred embodiments, the conditions include the provision of DMSO; the essentially constant temperature is  
10 at least 43°C, and most preferably between 50°C and 70°C; the conditions include a strand separation agent such as a helicase, at least one nucleotide triphosphate, selected from a protein having an activity corresponding to the RecA protein of *E. coli*, or a single-stranded nucleic acid  
15 binding protein; the DNA polymerase is a 5' exominus *Bst* DNA polymerase I or a modified *Taq* DNA polymerase; and at least one of the oligonucleotide primers includes a 5' non-complementary region. The RecA protein is not necessary for amplification in this invention, but rather can  
20 be used to enhance such amplification.

By "5' exonuclease minus" is meant that the nucleic acid polymerase has essentially no 5' exonuclease activity associated with it, or has been treated such that the exonuclease activity is reduced or inactive. The preferred  
25 nucleic acid polymerase is a 5' exonuclease minus DNA polymerase. Examples of DNA polymerases having no 5' exonuclease activity include a proteolytic fragment of DNA polymerase I from *Bacillus stearothermophilus*, and the DNA polymerase from *Thermus aquaticus* having its domain  
30 encoding 5' exonuclease activity removed as described by Barnes, "Thermostable DNA Polymerase," PCT/US91/07084. The exonuclease minus polymerase of the Klenow fragment described by Walker, *supra*, may also be used.

In a related aspect, the invention features a method  
35 and means for amplifying a nucleic acid target sequence by the step of contacting the nucleic acid containing the target sequence with a nucleic acid polymerase that may

have 5' exonuclease activity but under conditions wherein such activity is inhibited. Specifically, at least one oligonucleotide primer is modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in the nucleic acid polymerase. Preferably, at least one complementary and one sense primer is modified to be resistant to 5'-exonuclease activity. More preferably all primers are resistant to such degradation.

Thus in this aspect, the contacting step contains four different nucleotide triphosphates, at least two different complementary oligonucleotide primers and at least two different oligonucleotide sense primers, one or more of which are blocked. The reaction is carried out under oligonucleotide primer extension conditions at essentially constant temperature in the absence of a restriction endonuclease active on the products of any extension reaction of the contacting step.

In related aspects, amplification is carried out using a primer array and either a 5'-exo-minus DNA polymerase or a DNA polymerase containing 5' exonuclease activity used in conjunction with a 5'-exonuclease resistant primers.

As noted above, the present invention does not require a restriction endonuclease active on the products of any primer extension reaction resulting from the contacting step. In contrast to the description in Walker, *supra*, where the presence of such activity appears to be essential, Applicant has surprisingly found that no restriction enzyme is needed to create a single-stranded region which can be used by oligonucleotide primers in the contacting step.

Thus, in another aspect the invention features a method for amplifying a target nucleic acid sequence by contacting a nucleic acid strand containing the target sequence with a nucleic acid polymerase lacking 5' exonuclease activity, four different nucleotides, a set of at least two complementary oligonucleotide primers, and a set

of at least two sense primers. The amplification is carried out under primer extension conditions at essentially constant temperature in the absence of any restriction endonuclease active on the products of any extension reaction. The amplification is preferably carried out as described above.

In related aspects amplification is performed without any restriction endonuclease active on the products of any extension reaction using a nucleic acid polymerase containing 5' exonuclease activity in conjunction with a 5'-exonuclease-resistant primer; or a single stranded DNA substrate and either a 5'-exo-minus DNA polymerase or a DNA polymerase containing 5' exonuclease activity used in conjunction with a 5'-exonuclease-resistant primer. Such amplifications are preferably carried out as described above.

In this invention, amplification can be allowed to proceed for any desired length of time with product accumulating as a result of amplification of the target sequence. Where the target sequence is of analytical interest, high sensitivity detection of the target sequence can be accomplished by amplifying the target in the manner of the present invention and then detecting the accumulated amplification product using techniques known in the art.

The present amplification method provides a number of significant benefits. The present method requires only a nucleic acid polymerase as opposed to several different enzymes, amplification of a specific nucleic acid sequence is more efficient and requires less reagent than a random amplification process, and there is no need for time-consuming and cumbersome thermal cycling.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments, and from the claims.

### Brief Description of the Drawing

The Figure is an example illustrating the location of primers relative to each other and a target sequence. The Figure shows four complementary primers ("-"), four sense ("+") primers, and the location of a target sequence (rectangular box).

### Description of the Preferred Embodiments

The present invention features methods for amplifying a target nucleic acid sequence present in a nucleic acid, or a mixture of nucleic acids, by a process which includes synthesis of nucleic acid sequences in a specifically-primed template-dependent manner with a nucleic acid polymerase (e.g., a DNA polymerase) and oligonucleotides primers, preferably, a primer array. A primer array is made up of a set of complementary primers and a set of sense primers. Nucleic acid synthesis is initiated at a complementary primer. Without being bound to any theory, it is believed that primer-dependent synthesis occurring from one primer causes strand displacement of a strand synthesized from a different primer.

Thus, the amplification can be performed without modifying reaction conditions such as temperature, pH, or ionic strength during the amplification procedure to alternatively carry out amplification and denature the double-stranded nucleic acid produced during amplification. In addition, amplification can be performed without producing single-stranded substrates using enzymes having exonuclease activity or restriction endonuclease activity.

The process includes the step of priming template nucleic acid strands with a primer array of sequence-specific oligonucleotide primers, for each different target sequence to be amplified. The mixture is incubated in the presence of a nucleic acid polymerase, nucleotide substrates, and any necessary co-factors needed to amplify the target nucleic acid sequence.

As a result of the methods described herein, multiple rounds of template-dependent nucleic acid synthesis occur, concomitant with strand displacement of the previously synthesized strand. The displaced strand can act as a  
5 template in conjunction with the "sense primers", which now act as complementary primers.

#### Oligonucleotide Primer

The term "primer" refers to an oligonucleotide (whether occurring naturally as in a purified restriction  
10 digest, or produced synthetically) which can act as a point of initiation of nucleic acid synthesis on a nucleic acid template when contacted under primer extension conditions. Appropriate conditions include the presence of nucleotide substrates, a nucleic acid polymerase (e.g.,  
15 a 5'-exo-minus DNA polymerase), essentially constant temperature and a suitable pH. The nucleic acid synthesis occurs in a template-dependent manner wherein the sequence of the newly synthesized nucleic acid strand is complementary to the sequence of the nucleic acid template.

20 Hybridization of the primer to the template may be inhibited by primer secondary structure arising from intramolecular or intermolecular hydrogen bonding. Thus the primer preferably lacks secondary structure and is single-stranded. A primer having a secondary structure  
25 which would inhibit hybridization to the template is preferably treated to denature or separate its strand(s) prior to amplification.

Preferably, the primer is an oligodeoxynucleotide and is sufficiently long to be used as a substrate for the  
30 synthesis of extension products by a nucleic acid polymerase. The appropriate primer length should take into account several factors, including temperature, structure of primer, and how the primer is used. For example, for diagnostic applications the oligonucleotide primer typi-  
35 cally contains at least 15 nucleotides depending on the complexity of the target sequence. Other applications may



require shorter oligonucleotide primers. It may be desirable to carry out these other application at cooler temperatures to form stable hybrid complexes with the template.

5 A nucleic acid polymerase as used in the invention refers to a chemical, physical, or biological agent which brings about the synthesis of either ribo- or deoxyribo-nucleotides into a nucleic acid polymer, or strand, in a template-dependent manner. Examples of nucleic acid  
10 polymerases include DNA polymerases. DNA polymerases bring about nucleic acid synthesis in a template-dependent manner in a 5' to 3' direction. Because of the complementarity between the template and the synthesized strand, this direction would be from a 3' region on the template  
15 to a 5' region on the template. The large fragment of DNA polymerase I from *Bacillus stearothermophilus* (*Bst* DNA polymerase I) lacking 5'-3' exonucleolytic activity is a preferred DNA polymerase. Other suitable DNA polymerases include Klenow polymerase and bacteriophage T7 DNA  
20 polymerase. The use of 5' blocked primers not susceptible to nucleolytic degradation should allow the use of DNA polymerases possessing 5'-3' exonucleolytic activity.

Complementary primers are selected to have a region complementary to the nucleic acid template. The primer  
25 sequence need not reflect the exact sequence of the template but must be able to hybridize with a template strand. Non-complementary bases can be interspersed into the primer provided the primer sequence has sufficient complementarity to hybridize with its corresponding  
30 sequence in the nucleic acid template such that the extension reaction can occur. The newly-formed extension product, once displaced, can act as a template for additional nucleic acid synthesis.

Preferably, the primers contain a non-complementary  
35 5' region. Thus, the preferred primer contains a complementary region enabling it to hybridize to the nucleic acid template, and a non-complementary region. The

presence of a non-complementary region has been found to enhance strand displacement.

The primer sequence can include one or more of the deoxyribonucleotide bases A, T, C, or G; and/or, one or  
5 more of the ribonucleotide bases A, U, C, or G and/or one or more modified nucleotide (deoxyribonucleotide or ribonucleotide) wherein the modification does not prevent hybridization of the primer to the nucleic acid, or elongation of the primer, or strand displacement.

10 Primers may be modified with chemical groups to enhance their performance or to facilitate the characterization of amplification products. For example, backbone-modified oligonucleotides such as phosphorothioates or methylphosphonates which are resistant to the nucleolytic  
15 activity of certain polymerases allow the use of such enzymes. Another example of modification involves using non-nucleotide linkers (e.g., Arnold et al., EPA 88 308 766-0) which do not interfere with elongation of the primer. Oligonucleotides containing mixtures of the  
20 desired modified and natural nucleotides may be used as well.

Primers may also contain reactive sites for enzymes such as restriction endonuclease cleavage sites or promotor sites for RNA polymerases. Examples of the use  
25 of such sites include cloning of amplification products and transcription of amplification products after amplification. Such sites are not necessary for amplification, but are helpful for subsequent manipulations of the amplified nucleic acids.

30 The primers of the present invention can be prepared by methods known in the art. Preferably, the primers are synthesized by chemical methods. For example, Caruthers et al., in: Methods In Enzymology, vol. 154, p. 287 (1987), describe using standard phosphoramidite solid-  
35 phase chemistry to join nucleotides by phosphodiester linkages. Bhatt, U.S. Serial No. 07/319,570 entitled "Method and reagent for sulfurization of organophosphorous

compounds" filed 3/6/89, assigned to Gen-Probe Incorporated, the assignee of the present invention, describe a procedure for synthesizing oligonucleotides containing phosphorothioate linkages. Klem et al.,  
5 entitled "Improved process for the synthesis of oligomers" PCT WO92/07864, describe the synthesis of oligonucleotides having different linkages including methylphosphonate linkages. (These references are hereby incorporated by reference herein.)

10 Automated synthesizers are well suited for oligonucleotide synthesis. In an automated synthesizer, one starts with a 5'-protected, immobilized (through the 3'-hydroxyl) nucleoside residue. After 5'-deprotection, a phosphite ester linkage is introduced by reaction with  
15 a 3'-phosphoramidite, 5'-protected nucleoside residue. The phosphite linkage is then oxidized to a stable linkage and the process is cycled with the desired nucleotide residues introduced into the synthesized sequence. The oxidative procedure can result in a typical phosphate  
20 ester or a phosphorothioate ester (Arnold et al., *supra*, EPA 88 308 766-0). Introduction of non-nucleotide phosphoramidite derivatives can be performed during automated synthesis. Also, the synthesized oligonucleotide can be further modified by synthetic methods (e.g., as described  
25 in U.S. Pat. No. 4,818,681).

The 5' end of the primer can be modified to be resistant to 5'-exonuclease activity present in nucleic acid polymerase. Such modifications can be carried out by adding a non-nucleotide group to the terminal 5' nucleotide of the primer using techniques such as those  
30 described by Arnold et al., U.S. Serial No. 07/319,422, entitled "Non-nucleotide Linking Reagents for Nucleotide Probes," and the CLONTECH product catalogue describing the use of label-ON™ reagents, hereby incorporated by reference  
35 herein.

Test Sample

In general any source of nucleic acid, in purified or non-purified form, can be utilized as the starting nucleic acid or acids provided it contains or is suspected of containing the target nucleic acid sequence. Depending on the source and purity of the nucleic acid, the starting nucleic acid may need to be purified prior to amplification. Purification of starting nucleic acid is preferably carried out when the nucleic acid source contains substances which inhibit amplification. Nucleic acid purification can be carried out using standard techniques.

The target sequence may be present in DNA or RNA, which may be single-stranded or double-stranded. A mixture of these nucleic acids or the nucleic acid from a previous amplification may also be utilized. The nucleic acid or mixture of nucleic acids may contain more than one target nucleic acid sequence which may be the same or different. The invention is therefore useful for simultaneously amplifying one or more different target nucleic acid sequences located on the same or different target nucleic acid strands.

The sample suspected or known to contain the intended target nucleic acid may be obtained from a variety of sources. Such sources include a biological sample; a food or agricultural sample; an environmental sample; body fluid or exudate such as urine, blood, milk, cerebrospinal fluid, sputum, saliva, stool, lung aspirates; and throat or genital swabs.

It may be desirable to treat the test samples to obtain nucleic acids suitable for amplification. For example, in certain circumstances, it is desirable to treat the test sample to release, extract, or denature, the target nucleic acid prior to amplification. Such treatments can remove impurities which inhibit amplification, and denature the nucleic acid to minimize the secondary structure (i.e., double-stranded DNA and hairpin

loops). These treatments can be carried out by means well known in the art.

Primers are designed to hybridize to specified regions of the target nucleic acid. Two sets of primers are preferably used. One set of primers, complementary primers, are designed to hybridize to a nucleic acid sequence present on the template nucleic acid 3' to the target sequence. Hybridization takes place based on hydrogen bonding between complementary nucleotides. The other set of primers, sense primers, are designed to be analogous to regions present on the template nucleic acid 5' to the target sequence. The members of each primer set are co-linearly arranged as shown diagrammatically in the Figure.

Both sets of primers are positioned such that the target sequence, present in the template and the complement to the template, will be amplified. DNA polymerases catalyze nucleic acid synthesis in a 5' to 3' direction (with respect to the template nucleotides are added from a 3' template region to a 5' template region). A complementary strand is produced from the initial template using the complementary primer. The complementary strand can act as a template for template-dependent nucleic acid synthesis.

If the sense primer is analogous to a region on the nucleic acid template 5' to the target sequence, it will be complementary to a region 3' to the target sequence on the complementary strand. The sense primer can act as a complementary primer with respect to the complementary strand. Template-dependent nucleic acid synthesis can then occur on the complementary strand thereby producing more target sequence.

Different numbers of complementary and sense primers may be used to amplify a target sequence. It appears that as the number of primers increases, amplification increases. Thus, the total number of complementary primers and sense primers is preferably more than 5. In

preferred embodiments at least 4 sense primers and 4 complementary primers are used; at least 7 sense primers and 7 complementary primers are used; and at least 10 sense primers and 10 complementary primers are used. The number of complementary primers need not equal the number of sense primers. For example, a 2 sense primer and 3 complementary primer combination may be used.

When certain organic solvents such as DMSO are added to the amplification reaction and elevated temperature is used, substantial amplification as well as stringency is observed. If elevated temperature is used to increase strand displacement, a heat-stable nucleic acid polymerase such as a thermostable DNA polymerase may be employed. The temperature selected depends on the temperature range within which the enzyme is active.

The primers, nucleic acid polymerase, and nucleotides must be used in sufficient quantity to support the degree of amplification desired. Nucleotide analogs can be substituted or added provided the base pairing, DNA polymerase, and strand-displacing functions are not adversely affected to the point that the amplification does not proceed to the desired extent.

"Strand displacement" refers to the dissociation of a nucleic acid strand from its nucleic acid template in a 5' to 3' direction occurring due to template-directed nucleic acid synthesis by a nucleic acid polymerase. The newly synthesized and displaced nucleic acids have substantially the same nucleotide sequence which is complementary to the template nucleic acid sequence.

Preferably, a strand separation agent is used to enhance the strand displacement. Strand separation agents include enzymes such as helicases, the enzyme RecA which has helicase activity, and single-stranded nucleic acid binding protein. The use of helicases for separating strands of nucleic acid is described in Cold Spring Harbor Symposia on Quantitative Biology, Vol. XLIII, "DNA: Replication and Recombination" (New York: Cold Spring

Harbor Laboratory, 1978) and the use of RecA is reviewed by Radding, Ann. Rev. Genetics, 16: 405 (1982). Strand separation is discussed by Kornberg, A., DNA Replication W.H. Freeman & Co., San Francisco, CA., 1980. Zarling et al., U.S. Patent No. 5,223,414 (Jun, 1993) discusses the use of RecA in nucleic acid hybridization and amplification.

Amplification, as discussed above, refers to increasing the number of target sequences. The degree of amplification can be increased by using conditions or agents which increase rates or extent of priming, or primer elongation. For example, a strand separation agent may increase the strand displacement rate of a DNA polymerase.

A wide variety of methods are available to detect a target sequence. For example, the nucleotide substrates or the primers can include a detectable label which is incorporated into newly synthesized DNA. The resulting labeled amplification product is then separated from the unused labeled nucleotides or primers and the label is detected in the separated product fraction.

Substances which serve as useful detectable labels are well known in the art and include radioactive isotopes (e.g.,  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{125}\text{I}$ , and  $^{14}\text{C}$ ), fluorescent compounds, chemiluminescent compounds, chromophores, as well as ligands such as biotin and haptens which, while not directly detectable, can be readily detected by reaction with labeled forms of their specific binding partners, e.g., avidin and antibodies, respectively.

Another approach is to detect the amplification product by hybridization with a detectable nucleic acid probe and measuring the resulting hybrids in any conventional manner. In particular, the product can be assayed by hybridizing a chemiluminescent acridinium ester-labeled nucleic acid probe to the target sequence, selectively hydrolyzing the acridinium ester present on unhybridized probe, and measuring the chemiluminescence produced from

the remaining acridinium ester in a luminometer. (See, e.g., Arnold et al., supra, PCT US88/02746, and Nelson et al., in Nonisotopic DNA Probe Techniques, p. 275 Academic Press, San Diego (Kricka, ed., 1992) (both references hereby incorporated by reference herein).

### Examples

The present invention will now be illustrated, but is not intended to be limited, by the following examples.

#### Example 1: Amplification of an RNA Target

10 This example illustrates the amplification of a ribosomal RNA (rRNA) target sequence by producing a DNA template, and amplifying the DNA template using a primer array and a 5'-exo-minus DNA polymerase. Production of the DNA template from rRNA, and amplification of the  
15 template, was carried out in the same reaction vessel containing the necessary reagents for production and amplification of the DNA template.

The primer array used in this example comprised thirteen primers. The primers were prepared by standard  
20 phosphoramidite chemistry. Seven of the primers were complementary primers (with respect to the rRNA target). These primers had the following nucleic acid sequences (written 5' to 3'):

SEQ. ID. NO. 1:	CGCGTCTAGT CCTACTCAGG TGTTC
25 SEQ. ID. NO. 2:	CCCCAGATTC AGACTAGG
SEQ. ID. NO. 3:	CGGTCATTGA CTAGTATTTA GCCTT
SEQ. ID. NO. 4:	TTTCTTCATA GTACTGGTTC ACT
SEQ. ID. NO. 5:	ATTTCACTCC CTTAACAAGG GTT
SEQ. ID. NO. 6:	TTGTAAGCTA CAGGTTTCAG GT
30 SEQ. ID. NO. 7:	ACGGGCAATT GGTCTGCGAC C

Six of the primers were sense primers (with respect to the rRNA target). These primers had the following nucleic acid sequences (written 5' to 3'):

SEQ. ID. NO. 8:	AGCAAAGACC CGGAGGTCCG AAT
35 SEQ. ID. NO. 9:	GAATACATAG GTATGCAAAG CGA



SEQ. ID. NO. 10: CCTGCCGAAC TGAAACATCT TAGT  
SEQ. ID. NO. 11: CAGAGGAAAA GAAATCGAAG AGAT  
SEQ. ID. NO. 12: TGTAGGATTG AGGATAAAGG AT  
SEQ. ID. NO. 13: GGACTCCTAG TTGAACACAT CTGGAAAGA.

5 Target 23S rRNA was obtained from *Chlamydia trachomatis* (See, Glisin et al., Biochemistry 13:2633 (1974)), and diluted in buffer (50 mM Tris-HCl (pH 8.3), 37.5 mM KCl, 1.5 mM MgCl<sub>2</sub>, 10 mM DTT). Variable amounts of rRNA target were combined with primers ( $7 \times 10^{-12}$  mole) in  
10 20  $\mu$ l of buffer (7% DMSO, 50 mM Tris-HCl (pH 8.3) 75 mM KCl, 3 mM MgCl<sub>2</sub>, and 2 mM DTT) and incubated at 60°C for 30 minutes to pre-hybridize the primers. The pre-ybridized primers were then treated with 0.2 mM ATP, 0.2 mM TTP, 0.2 mM GTP, 0.2 mM CTP, 200 units of Maloney  
15 Murine Leukemia Virus reverse transcriptase (MMLV-RT), and 2 units of *Bst* DNA polymerase I. Amplification was carried out at 37°C for 60 minutes, then at 60°C for 120 minutes.

The amplification products were then denatured and  
20 assayed using acridinium ester labeled probe according to Nelson et al., supra. Denaturation was carried out by incubating at 95°C for 5 minutes. Probe labeling with acridinium ester was carried out as described by Nelson et al., supra. The acridinium ester labeled probe was syn-  
25 thesized to have the nucleic acid sequence corresponding to SEQ. ID. NO. 27. The acridinium ester labeled probe ( $2 \times 10^{-11}$  moles) was incubated with amplified product at 60°C for 15 minutes in 100  $\mu$ l of hybridization buffer (100 mM lithium succinate (pH 5.2), 8% lithium dodecyl sulfate,  
30 1.5 mM EDTA, and 1.5 mM EGTA). The acridinium ester present on unhybridized probe was then hydrolyzed by adding a reagent solution (0.15 M sodium tetraborate, pH 7.6, and 5% (v/v) Triton X-100) and incubating at 60°C for 10 minutes. The remaining chemiluminescence was measured  
35 in a luminometer. The results shown in Table 1 demonstrate a titration of the target nucleic acid in the amplification method of the present invention.

Table 1

	<u>Chlamydia rRNA (Moles)</u>	<u>RLU (mean)</u>
	4 x 10 <sup>-18</sup>	307893
	4 x 10 <sup>-19</sup>	54771
5	4 x 10 <sup>-20</sup>	3644
	4 x 10 <sup>-21</sup>	2354
	0	2307

Example 2: Amplification of a Clinical Specimen

This example illustrates the amplification of an rRNA target sequence present in a clinical sample (cervical swab sample). The oligonucleotides, amplification procedure, and detection procedure used in this example were as described in Example 1. This example differs from Example 1 in the type of sample used, and sample preparation.

Cervical swab samples were collected and suspended in a buffered solution containing an anionic detergent (60 mM phosphate buffer (pH 6.8), 6% lithium dodecyl sulfate, 2 mM EDTA, and 2 mM EGTA). The clinical specimen was spiked with 10<sup>-18</sup> moles of 23S *Chlamydia trachomatis* rRNA, hybridized with the primers, amplified, and detected, as described in Example 1. A successful amplification of target nucleic acid in the clinical sample was indicated by the clinical sample with *Chlamydia* rRNA having an RLU over 50 fold greater than a clinical sample without *Chlamydia* rRNA.

Example 3: Specificity of Amplification

This example illustrates the amplification of a specific target sequence using probes directed to a target sequence and a non-target sequence (i.e., a region of the transcript outside the amplicon). The target nucleic acid used in this example was derived from gene 10 of T7 bacteriophage. In particular, an XmaI and BanI digest of pGEMX1 containing part of gene 10 of T7 bacteriophage was sub-cloned into pUC19. Expression of the insert with T7

RNA polymerase yielded an RNA product 863 bases in length and this transcript was used to produce a DNA template which was then amplified.

The primer array, used to amplify the target  
5 sequence, was made up of four complementary primers (with respect to the RNA transcript) having the following nucleic acid sequences (written 5' to 3'):

SEQ. ID. NO. 14 CTATAGGGAG ACCACAACGG TTT  
SEQ. ID. NO. 15 CTAGAAATAA TTTTGTTTAA CTT  
10 SEQ. ID. NO. 16 AGAAGGAGAT ATACATATGG CT  
SEQ. ID. NO. 17 CATGACTGGT GGACAGCAAA TG

and four primers having the same sense as the RNA transcript, having the following nucleic acid sequences (written 5' to 3'):

15 SEQ. ID. NO. 18 GAGCGAACGC AGTCAGGA  
SEQ. ID. NO. 19 GAGAAGTGGT CACGGAGGTA CGAGCGAACG CAGT  
SEQ. ID. NO. 20 GGAGATGGAA CGTACCATGT  
SEQ. ID. NO. 21 GGGAAGTGGT CGGATTTACC GC

Hybridization, amplification, and detection were  
20 carried out as described in Example 1. Acridinium ester-labeled probes, SEQ. ID. NO. 22 and SEQ. ID. NO. 27 were used to detect the presence of the target sequence. A non-target acridinium ester labeled probe (SEQ. ID. NO. 23) was used as a control to determine non-specific  
25 amplification occurring outside the primer region (e.g., 3' of the complementary primers and 5' the sense primers). The results shown in Table 2 demonstrate that the amplification is specific.

Table 2

30	<u>Probe</u>	<u>Sample</u>	<u>RLU(mean)</u>
	SEQ. ID. 22		
	+	(4 x 10 <sup>-19</sup> mole)	240474
	SEQ. ID. 27		
	SEQ. ID. 23	(4 x 10 <sup>-19</sup> mole)	3091
35	SEQ. ID. 23	no target	2720

Example 4: Enhanced Strand Displacement

This example demonstrates the ability of a non-complementary region, attached to a primer, to enhance strand displacement and amplification. Strand displacement was measured using two different combinations of complementary primers. Both combinations contained a 5'-<sup>32</sup>P labeled primer (SEQ. ID. NO. 19) and an additional primer. The additional primer in one combination corresponded to SEQ. ID. NO. 24. The additional primer in the other combination corresponded to SEQ. ID. NO. 25. The SEQ. ID. NO. 25 primer was similar to the SEQ. ID. NO. 24 primer, but had five fewer complementary nucleotides and contained a 5' non-complementary region. Amplification was carried out on an oligodeoxynucleotide template corresponding to a portion of the T7 bacteriophage gene 10. The template, corresponding to SEQ. ID. NO: 26, was synthesized as described in Example 1.

The primers ( $4 \times 10^{-12}$  mole) were prehybridized with template ( $4 \times 10^{-13}$  mole) in 20  $\mu$ l of buffer (50 mM Tris-HCl (pH 8.3), 37.5 mM KCl, 1.5 mM MgCl<sub>2</sub>, 10 mM DTT), by incubating at 70°C for 5 minutes, and the reaction was then allowed to cool to room temperature (about 20-25°C) over the course of about 2 hours. Amplification was carried out by adding 0.1 mM ATP, 0.1 mM TTP, 0.1 mM GTP, 0.1 mM CTP, 4 units *Bst* DNA polymerase I and incubating at 50°C. Time points were taken at 5, 15, and 30 minutes by transferring aliquots of the reaction to a formamide/EDTA solution (50% formamide 10 mM Tris-HCl pH 8.0, 0.1 mM EDTA). The samples were loaded and run on a denaturing 15% polyacrylamide gel. Bands corresponding to the elongation product and primer were excised from the gel and analyzed by Cerenkov counting in a scintillation counter.

The results shown in Table 3 demonstrate that strand displacement is more efficient using primers with a 5' non-complementary region. The "% product" refers to the amount of elongation product divided by the sum of the

amount of elongation product and primer. The higher percentage of product observed with the primer having a 5' non-complementary region indicates increased amplification and strand displacement.

5 Table 3

Primer (SEQ. ID. NO) <sup>1</sup>	24	24	24	25	25	25
Time	5 min	15 min	30 min	5 min	15 min	30 min
% Product	4.3	5.8	5.9	18	25	35

10 <sup>1</sup>. In addition to the primers listed in Table 4, each reaction mixture contained a radiolabeled primer having the nucleotide sequence of SEQ. ID. NO. 19.

The present embodiments of this invention are to be considered in all respects as illustrative and not  
15 restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims therefore are intended to be embraced therein.

20 Other embodiments are within the following claims.

## SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANT: Gen-Probe Incorporated
- (ii) TITLE OF INVENTION: ISOTHERMAL STRAND  
5 DISPLACEMENT NUCLEIC  
ACID AMPLIFICATION
- (iii) NUMBER OF SEQUENCES: 27
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Gen-Probe Incorporated
- 10 (B) STREET: 9880 Campus Point Drive
- (C) CITY: San Diego
- (D) STATE: California
- (E) COUNTRY: USA
- (F) ZIP: 92121
- 15 (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
storage
- (B) COMPUTER: IBM Compatible
- (C) OPERATING SYSTEM: IBM P.C. DOS (Version  
20 5.0)
- (D) SOFTWARE: WordPerfect (Version  
5.1)
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
- 25 (B) FILING DATE:
- (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- Prior applications total,  
including application  
30 described below: none
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Heber, Sheldon O.
- 35 (B) REGISTRATION NUMBER: 38,179
- (C) REFERENCE/DOCKET NUMBER: 207/140
- (ix) TELECOMMUNICATION INFORMATION:

29

(A) TELEPHONE: (619) 535-2807  
(B) TELEFAX: (619) 452-5848  
(C) TELEX: 67-3510

(2) INFORMATION FOR SEQ ID NO: 1:

5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 25  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 1:  
CGCGTCTAGT CCTACTCAGG TGTTG 25

(3) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
15 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 2:  
CCCCAGATTC AGACTAGG 18

20 (4) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 25  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
25 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 3:  
CGGTCATTGA CTAGTATTTA GCCTT 25

(5) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:  
30 (A) LENGTH: 23  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 4:  
35 TTTCTTCATA GTACTGGTTC ACT 23

(6) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 23  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 5:  
ATTTCACTCC CTTAACAAGG GTT 23

(7) INFORMATION FOR SEQ ID NO: 6:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22  
10 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 6:  
TTGTAAGCTA CAGGTTTCAG GT 22

15 (8) INFORMATION FOR SEQ ID NO: 7:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
20 (D) TOPOLOGY: linear  
(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 7:  
ACGGGCAATT GGTCTGCGAC C 21

(9) INFORMATION FOR SEQ ID NO: 8:  
(i) SEQUENCE CHARACTERISTICS:  
25 (A) LENGTH: 23  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 8:  
30 AGCAAAGACC CGGAGGTCCG AAT 23

(10) INFORMATION FOR SEQ ID NO: 9:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23  
(B) TYPE: nucleic acid  
35 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 9:



31

GAATACATAG GTATGCAAAG CGA 23

(11) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 10:

CCTGCCGAAC TGAAACATCT TAGT 24

10 (12) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 11:

CAGAGGAAAA GAAATCGAAG AGAT 24

(13) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 12:

25 TGTAGGATTG AGGATAAAGG AT 22

(14) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 13:

GGACTCCTAG TTGAACACAT CTGGAAAGA 29

(15) INFORMATION FOR SEQ ID NO: 14:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

32

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 14:  
CTATAGGGAG ACCACAACGG TTT 23

5 (16) INFORMATION FOR SEQ ID NO: 15:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
10 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 15:  
CTAGAAATAA TTTTGTTTAA CTT 23

(17) INFORMATION FOR SEQ ID NO: 16:  
(i) SEQUENCE CHARACTERISTICS:  
15 (A) LENGTH: 22  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 16:  
20 AGAAGGAGAT ATACATATGG CT 22

(18) INFORMATION FOR SEQ ID NO: 17:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22  
(B) TYPE: nucleic acid  
25 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 17:  
CATGACTGGT GGACAGCAAA TG 22

(19) INFORMATION FOR SEQ ID NO: 18:  
30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

35 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 18:  
GAGCGAACGC AGTCAGGA 18

(20) INFORMATION FOR SEQ ID NO: 19:

33

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

5 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 19:

GAGAAGTGGT CACGGAGGTA CGAGCGAACG CAGT 34

(21) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 20:

15 GGAGATGGAA CGTACCATGT 20

(22) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 21:

GGGAACTGAG CGGATTTACC GC 22

(23) INFORMATION FOR SEQ ID NO: 22:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 22:

30 GAACAACGCC AGTTTGATCT CCAGCAG 27

(24) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

35 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 23:  
CAACCTCAAA GGCCCATAAAC GTTGCG 26

(25) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 29  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 24:  
10 GTCAGGACTT CACCGCCAAA TACCTTCAA 29

(26) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 50  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 25:  
GAAATTAATA CGACTCACTA TAGGGAGACT TCACCGCCAA ATACCTTCAA 50

(27) INFORMATION FOR SEQ ID NO: 26:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 137  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 26:  
CATGACTGGT GGACAGCAAA TGGGTACTAA CCAAGGTAAA GGTGTAGTTG  
CTGCTGGAGA TAAACTGGCG TTGTTCTTGA AGGTATTTGG CGGTGAAGTC  
CTGACTGCGT TCGCTCGTAC CTCCGTGACC ACTTCTC 137

(28) INFORMATION FOR SEQ ID NO: 27:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 27:  
35 CCCGTTAGACG AAAGGAGAGA AAGACCG 27

CLAIMS

1. A method for amplifying a nucleic acid target sequence, comprising the step of:

contacting a nucleic acid strand containing said  
5 target sequence with a nucleic acid polymerase lacking 5' exonuclease activity, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, at least three different complementary primers under oligonucleotide primer extension conditions  
10 at essentially constant temperature.

2. A method for amplifying a nucleic acid target sequence, comprising the step of:

contacting a nucleic acid strand containing said  
target sequence with a nucleic acid polymerase lacking 5'  
15 exonuclease activity, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, at least two different complementary primers in the absence of a restriction endonuclease active on products of any extension reaction of said contacting  
20 step, under oligonucleotide primer extension conditions at essentially constant temperature.

3. A method for amplifying a nucleic acid target sequence, comprising the step of:

contacting said target sequence with a nucleic acid  
25 polymerase, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, at least three complementary oligonucleotide primers, under oligonucleotide primer extension conditions at essentially constant temperature, wherein one said  
30 complementary primer is modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

4. A method for amplifying a nucleic acid target sequence, comprising the step of:

contacting said target sequence with a nucleic acid polymerase, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, at least two different complementary oligonucleotide primers, in the absence of a restriction endonuclease active on products of any extension reaction of said contacting step under oligonucleotide primer extension conditions at essentially constant temperature, wherein at least one said complementary primer is modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

5. The method of claim 1, wherein at least four said complementary primers are used.

6. The method of claim 2, wherein at least four said complementary primers are used.

7. The method of claim 5, wherein each of said complementary primers is separated by a distance of 1 to 200 nucleotides.

8. The method of claim 6, wherein each of said complementary primers is separated by a distance of 1 to 200 nucleotides.

9. A method for amplifying a nucleic acid target sequence, comprising the step of:

contacting a nucleic acid strand containing said target sequence with a nucleic acid polymerase lacking 5' exonuclease activity, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, a primer array of at least five different primers comprising two to three different complementary oligonucleotide primers and two to three different sense oligonucleotide primers, under oligonucleotide primer extension conditions at essentially constant temperature.

10. A method for amplifying a nucleic acid target sequence, comprising the step of:

contacting a nucleic acid strand containing said target sequence with a nucleic acid polymerase, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, a primer array of at least five different primers comprising two to three different complementary oligonucleotide primers and two to three different sense oligonucleotide primers, under oligonucleotide primer extension conditions at essentially constant temperature, wherein at least one said sense primer or at least one said complementary primer is modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

11. A method for amplifying a DNA target sequence, comprising the step of:

contacting a single stranded DNA containing said target sequence with a DNA polymerase lacking 5' exonuclease activity, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, a primer array of at least five different primers comprising two to three different complementary oligonucleotide primers and two to three different sense oligonucleotide primers, under oligonucleotide primer extension conditions at essentially constant temperature.

12. A method for amplifying a DNA target sequence, comprising the step of:

contacting a single stranded DNA containing said target sequence with a DNA polymerase, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, a primer array of at least five different primers comprising two to three different complementary oligonucleotide primers and two to three different sense oligonucleotide primers,

under oligonucleotide primer extension conditions at essentially constant temperature, wherein at least one said sense primer or at least one said complementary primer is modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

13. The method of claim 9, wherein at least 4 said sense primers and at least 4 said complementary primers are used.

10 14. The method of claim 9, wherein at least 7 said sense primers and at least 7 said complementary primers are used.

15 15. The method of claim 9, wherein at least 10 said sense primers and at least 10 said complementary primers are used.

16. The method of claim 9, wherein each adjacent said sense primer is separated by a distance of 1 to 200 nucleotides, and each adjacent said complementary primer is separated by a distance of 1 to 200 nucleotides.

20 17. The method of claim 13, wherein each adjacent said sense primer is separated by a distance of 1 to 200 nucleotides, and each adjacent said complementary primer is separated by a distance of 1 to 200 nucleotides.

25 18. The method of claim 14, wherein each adjacent said sense primer is separated by a distance of 1 to 200 nucleotides, and each adjacent said complementary primer is separated by a distance of 1 to 200 nucleotides.

19. The method of claim 15, wherein each adjacent said sense primer is separated by a distance of 1 to 200



nucleotides, and each adjacent said complementary primer is separated by a distance of 1 to 200 nucleotides.

20. The method of claim 16, wherein two adjacent sense primers are separated by a distance of up to 10 nucleotides, and two adjacent complementary primer are separated by a distance of up to 10 nucleotides.

21. A method for amplifying a nucleic acid target sequence, comprising the step of:

contacting a nucleic acid strand containing said target sequence with a nucleic acid polymerase lacking 5' exonuclease activity, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, two different complementary oligonucleotide primers and two different sense oligonucleotide primers under oligonucleotide primer extension conditions at essentially constant temperature in the absence of a restriction endonuclease active on products of any extension reaction of said contacting step.

22. A method for amplifying a nucleic acid target sequence, comprising the step of:

contacting a nucleic acid strand containing said target sequence with a nucleic acid polymerase, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, two different complementary oligonucleotide primers and two different sense oligonucleotide primers under oligonucleotide primer extension conditions at essentially constant temperature in the absence of a restriction endonuclease active on products of any extension reaction of said contacting step, wherein at least one said sense primer or one said complementary primer is modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

23. A method for amplifying a DNA target sequence, comprising the step of:

contacting a single stranded DNA containing said target sequence with a DNA polymerase lacking 5' exonuclease activity, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate,, two different complementary oligonucleotide primers and two different sense oligonucleotide primers under oligonucleotide primer extension conditions at essentially constant temperature in the absence of a restriction endonuclease active on products of any extension reaction of said contacting step.

24. A method for amplifying a DNA target sequence, comprising the step of:

contacting a single stranded DNA containing said target sequence with a DNA polymerase, at least one nucleotide triphosphate selected from adenosine, thymidine, guanosine and cytosine triphosphate, two different complementary oligonucleotide primers and two different oligonucleotide sense primers under oligonucleotide primer extension conditions at essentially constant temperature in the absence of a restriction endonuclease active on products of any extension reaction of said contacting step, wherein at least one said sense primer or one said complementary primer is modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

25. The method of claim 23, wherein said conditions include provision of DMSO.

26. The method of claim 23, wherein said essentially constant temperature is at least 43°C.

27. The method of claim 26, wherein said essentially constant temperature is between 60°C and 70°C.

28. The method of claim 23, wherein said conditions include provision of a strand-displacing agent.

29. The method of claim 28, wherein said strand-displacing agent is selected from the group consisting of  
5 a helicase, a RecA protein, and a single-stranded nucleic acid binding protein.

30. The method of claim 23, wherein said DNA polymerase is *Bst* DNA polymerase I or a modified *Taq* DNA polymerase.

10 31. The method of claim 23, wherein at least one of the oligonucleotide primers further comprises a 5' non-complementary region.

32. The method of claim 23, wherein at least 4 said complementary primers, and at least 4 said sense primers,  
15 are used.

33. The method of claim 23, wherein at least 7 said complementary primers, and at least 7 said sense primers, are used.

34. The method of claim 23, wherein at least 10 said  
20 sense primers, and at least 10 said complementary primers, are used.

35. The method of 10, wherein at least one said sense primer and one said complementary primer are modified to be resistant to nucleolytic degradation by any  
25 5'-exonuclease present in said contacting step.

36. The method of claim 12, wherein at least one said sense primer and one said complementary primer are modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

37. The method of claim 22, wherein at least one said sense primer and one said complementary primer are modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

- 5 38. The method of claim 24, wherein at least one said sense primer and one said complementary primer are modified to be resistant to nucleolytic degradation by any 5'-exonuclease present in said contacting step.

1 / 1




FIGURE 1

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/03339

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP-A-0 395 398 (LIFE TECHNOLOGIES INC) 31 October 1990	1,2,5-7, 9,11-18
Y	see page 2, line 50 - page 8, line 33; claims 1-16	3,4,8, 10,19-22
	---	
X	EP-A-0 543 612 (BECTON DICKINSON CO) 26 May 1993	1,2,5-7
	see page 5, line 33 - page 10, line 34	
	---	
Y	EP-A-0 500 224 (BECTON DICKINSON CO) 26 August 1992	3,4,8,10
	cited in the application	
	see column 7, line 38 - column 10, line 35; claims 1-13; figures 1,2	
	---	
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

- \* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* "&" document member of the same patent family

Date of the actual completion of the international search

21 June 1995

Date of mailing of the international search report

- 3. 07. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Hornig, H

# INTERNATIONAL SEARCH REPORT

Internat'l Application No  
PCT/US 95/03339

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP-A-0 497 272 (BECTON DICKINSON CO) 5 August 1992 cited in the application see page 4, line 28 - page 5, line 21 see page 7, line 41 - line 45; claims 3,9 ----	19,21,22
Y	EP-A-0 200 362 (CETUS CORPORATION) 10 December 1986 see claim 9 -----	20
A	ANALYTICAL BIOCHEMISTRY, vol. 132, ACADEMIC PRESS INC., DULUTH, MN, US, pages 6-13, A.P. FEINBERG AND B. VOGELSTEIN 'A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity' cited in the application see page 7, right column, line 21 - page 12, right column, line 18 -----	1-22

# INTERNATIONAL SEARCH REPORT

Interno I Application No  
PCT/US 95/03339

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0395398	31-10-90	US-A- 5043272	27-08-91
		CA-A- 2013800	27-10-90
		JP-A- 2303489	17-12-90
		US-A- 5106727	21-04-92
EP-A-0543612	26-05-93	US-A- 5270184	14-12-93
		AU-A- 2849992	20-05-93
		CA-A- 2082842	20-05-93
		JP-A- 5276947	26-10-93
EP-A-0500224	26-08-92	AU-A- 8997991	06-08-92
		CA-A- 2058567	01-08-92
		JP-A- 5130870	28-05-93
EP-A-0497272	05-08-92	AU-B- 652214	18-08-94
		AU-A- 1026492	06-08-92
		AU-B- 659429	18-05-95
		CA-A- 2060371	01-08-92
		CA-A- 2060372	01-08-92
		JP-A- 5192195	03-08-93
		AU-A- 1069992	29-07-93
		KR-B- 9503619	17-04-95
EP-A-200362	05-11-86	US-A, B 4683202	28-07-87
		US-A- 4683195	28-07-87
		AU-B- 586233	06-07-89
		AU-A- 5532286	02-10-86
		AU-B- 591104	30-11-89
		AU-A- 5532386	02-10-86
		CA-A- 1237685	07-06-88
		DE-A- 3687287	28-01-93
		DE-A- 3687537	04-03-93
		DE-T- 502588	16-12-93
		DK-A- 26595	17-03-95
		EP-A, B 0201184	12-11-86
		EP-A- 0502588	09-09-92
		EP-A- 0509612	21-10-92
		EP-A- 0505012	23-09-92
		EP-A- 0502589	09-09-92
		HK-A- 84094	26-08-94



# INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT/US 95/03339

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-200362		HK-A- 84994	26-08-94
		JP-B- 4067957	29-10-92
		JP-A- 62000281	06-01-87
		JP-B- 4067960	29-10-92
		JP-A- 61274697	04-12-86
		JP-A- 6007166	18-01-94
		JP-A- 5308971	22-11-93
		SG-A- 111193	25-02-94
		SG-A- 111293	25-02-94
		US-A- 5386022	31-01-95
		US-A- 5176995	05-01-93
		US-A- 4800159	24-01-89